Beacon Biosignals

We're excited to announce that Takeda and Beacon Biosignals have entered a strategic collaboration to conduct at-home sleep monitoring to support clinical trials in the Takeda orexin franchise and neuroscience portfolio! Takeda will leverage Beacon's neurophysiology platform, including the FDA-cleared Dreem 3S EEG headband, AI-powered analytics, and clinico-EEG database. ? Quantitative sleep data has been historically difficult to collect and analyze at the speed and scale necessary to support clinical development. This collaboration enables Takeda to collect lab-quality sleep data from a patient's home, longitudinally and at-scale, to characterize sleep dysfunction and enable more personalized treatment options. “Takeda is committed to developing life-transforming therapies for areas of highest unmet need, including narcolepsy and other sleep-wake disorders. In partnering with Beacon, we will now have access to real-time, longitudinal sleep data that better reflects the daily burden of living with these disorders,” said Elena Koundourakis, head of the Orexin Franchise Development and Neuroscience Portfolio Strategy at Takeda. “The Beacon Platform will be used to inform our clinical trial designs including defining quantitative, digital endpoints based on objective measures of sleep patterns, which could support more tailored treatment approaches and improve the diagnostic journey for patients.” ? We're committed to improving the patient experience and operationalizing at-home sleep endpoints at-scale, and we're thrilled to work with Takeda to pave the way towards novel therapeutic approaches for neurological and psychiatric indications. Full press release: https://lnkd.in/gERHr48j To learn more about Beacon: https://lnkd.in/errYwFaE #takeda #beacon #collaboration #EEG #Dreem #narcolepsy #orexin

We're excited to continue supporting Takeda and Type 1 #Narcolepsy patients globally with our #FDA-cleared wearable EEG platform! Diagnosing and treating sleep disorders at scale - and at home - represent an enormous opportunity to better serve patients and the communities that support them. We're thrilled to be partnering with Takeda and the patient community on this mission!

Beacon Biosignals is at CNS Summit in Boston this week! Come say hi to Jacob Donoghue, David Matthews, and Corey Puryear and chat about novel approaches to #PrecisionMedicine in psychiatry and neurodegenerative disease.

We’re growing and growing and now sponsoring PhD students! Come work with Yves Dauvilliers and the Beacon Biosignals team! Great marker of progress as we continue to invest in the next generation of scientists pushing forward the fields of machine learning and sleep medicine.

Beacon Biosignals is growing! We're looking for a passionate, experienced Senior Marketing and Communications Manager to join us in revolutionizing precision medicine for the brain. As the first full-time marketing professional at Beacon, you’ll work directly with our Chief Business Officer, David Matthews, to shape and execute a range of strategies to work with our customers developing therapies across neurological, psychiatric, and sleep-related conditions with the help of our FDA 510(k)-cleared EEG headband and SAMD algorithms. If you like to build and have experience in healthcare or biotech marketing, with a talent for communicating scientific concepts in an engaging way, let's talk. Apply now and be part of a mission-driven and patient-first team that’s driving precision medicine in neuroscience!

Engaging with patient perspectives, like those shared by Sleep Consortium, Inc. enhances our understanding of narcolepsy’s impact. We’re partnering with Beacon Biosignals, exploring how wearable tech could ease patient burden and help gather accurate information for sleep disorder diagnosis. Read the full story. https://lnkd.in/e2uDuwXt #OurStories.

HLTH Community Insider at HLTH USA: Revolutionising Sleep Health Through Partnerships ???? The HLTH Community Insider session on "Pharma Partnerships to Drive Digital Innovation in Sleep," in partnership with Takeda, has set a new benchmark for industry dialogue. Esteemed speakers who led the charge: - Julia Jackson and Sara Sarkey, Takeda - David Matthews, PhD, Beacon Biosignals - Jen Horonjeff, Savvy Cooperative - Chandana Fitzgerald, HLTH Community Key highlights: - Exploring synergies between pharma and tech in sleep innovation - Charting the course for enhanced patient outcomes via strategic collaborations Core insight: The confluence of pharmaceutical expertise and technological prowess is reshaping sleep health. We extend our gratitude to all participants for their invaluable contributions to this pivotal discussion. #HLTHUSA #SleepInnovation #DigitalHealth #HLTH We invite you to continue this critical conversation. How do you envision the future of sleep health innovation? Share your perspectives below. ??

See you tomorrow at #HLTH2024 where Beacon's David Matthews, PhD will be on stage with Julia Jackson and Sara Sarkey from our Beacon partner Takeda, along with Jen Horonjeff of Savvy Cooperative, for a discussion on supporting #narcolepsy patients with technology innovations in #EEG and #AI, all mediated by Chandana Fitzgerald, President of HLTH Inc. Community. See you soon!

I am proud that in our partnership with Takeda we continue to put the patient first. The burden of the diagnostic journey in narcolepsy and disorders of hypersomnia is often long and overwhelming—marked by delays, multiple tests, and the challenges of navigating traditional sleep labs. Together, we are focused on finding innovative solutions that shorten the time to diagnosis and reduce patient burden. At Beacon Biosignals, we aim to make precision diagnostics more accessible and empowering patients to receive timely, accurate care. With partnerships like this and harnessing our Dreem 3S wearable medical device, we’re reimagining the future of sleep diagnostics to drive real improvements in patient outcomes today. #PatientFirst #NarcolepsyAwareness #narcolepsy #Hypersomnia #Sleep #diagnostics

Congrats to our partners at Cerevance on this important milestone with Merck as they continue advancing the treatments of neurodegenerative, psychiatric and central nervous system disorders!